Mark A. Glickman - Dec 6, 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)

Role: Co-Chief Executive Officer
Signature: /s/ Mark A. Glickman
Stock symbol: TXMD
Transactions as of: Dec 6, 2022
Transactions value $: -$2,165
Form type: 4
Date filed: 12/9/2022, 06:38 PM
Previous filing: Mar 31, 2022
Next filing: May 12, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TXMD	Common Stock	Options Exercise	$0	+1.73K		$0.00	1.73K	Dec 6, 2022	Direct	F1
transaction	TXMD	Common Stock	Sale	-$2.17K	-440	-25.37%	$4.92	1.29K	Dec 6, 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TXMD	Restricted Stock Units	Options Exercise	$0	-1.73K	-33.35%	$0.00	3.47K	Dec 6, 2022	Common Stock	1.73K	$0.00	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 1,734 shares of issuer common stock in settlement of restricted stock units (RSUs).
F2	The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
F3	The RSUs will vest in three equal installments annually beginning October 15, 2022, becoming fully vested on October 15, 2024, subject in each case to the continued service of the reporting person with the issuer.